CRISPR Therapeutics director Ali Behbahani disposes of common shares worth $780,649.24

• CRISPR Therapeutics director Ali Behbahani exercised stock options for 30,000 common shares at USD 14 on Sept. 17, 2026.
• Behbahani sold 13,679 common shares at USD 57.09 on the same day.
• Directly held common shares totaled 16,637 following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CRISPR Therapeutics AG published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-396944), on September 21, 2026, and is solely responsible for the information contained therein.